RELAPSE
Clinical trials for RELAPSE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE trials appear
Sign up with your email to follow new studies for RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene-Edited immune cells take on tough lymphoma
Disease control OngoingThis early-phase study tests a new cell therapy for patients with relapsed EBV-positive lymphoma. The treatment uses the patient's own immune cells, modified to resist a tumor's defense mechanism (TGFb) and trained to attack cancer cells. The main goals are to find a safe dose an…
Matched conditions: RELAPSE
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 26, 2026 03:51 UTC
-
Gentler approach to tough myeloma: lower doses may help frail patients
Disease control OngoingThis study tests a combination of three drugs (isatuximab, pomalidomide, and dexamethasone) at lower-than-standard doses in people with multiple myeloma that has returned or not responded to treatment. The goal is to see if this gentler approach is safe and effective for patients…
Matched conditions: RELAPSE
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Phone Check-Ins may keep eating disorders at bay
Knowledge-focused OngoingThis study follows 250 people who have recovered from an eating disorder. Nurses will call them once a year for three years to check on their progress and spot any signs of relapse early. The goal is to learn how often relapses happen and what factors might increase the risk.
Matched conditions: RELAPSE
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated May 26, 2026 03:56 UTC